Serum Eosinophilic Cationic Protein Is a Reliable Biomarker for Childhood Asthma

Abstract

<b><i>Background:</i></b> Eosinophilic cationic protein (ECP) is associated with airway inflammation and asthma. However, the clinical value of measuring ECP in childhood asthma is not fully known. We aimed to study the diagnostic performance of serum ECP and other common asthma biomarkers, individually and in combinations. <b><i>Methods:</i></b> In a cross-sectional study, 5–16-year-old children with current asthma (CA) (<i>n</i> = 37), transient asthma (TA) (<i>n</i> = 43), (previous history of wheezing/asthma), and healthy children (HC) (<i>n</i> = 86) were investigated for ECP, blood eosinophil count (B-Eos), fractional exhaled nitric oxide (FeNO), and lung function, i.e., spirometry (forced expiratory volume during the first second [FEV1]/forced vital capacity [FVC] ratio). <b><i>Results:</i></b> Both ECP and B-Eos were higher in CA compared to TA (<i>p</i> &#x3c; 0.01) and HC (<i>p</i> &#x3c; 0.0001). ECP and B-Eos were also higher in TA compared to HC (<i>p</i> &#x3c; 0.05 and <i>p</i> &#x3c; 0.001, respectively). FeNO was higher in CA (<i>p</i> &#x3c; 0.0001) and TA (<i>p</i> &#x3c; 0.01) compared to HC but similar between the asthma groups. The FEV1/FVC ratio was lower in CA compared to TA and HC (both <i>p</i> &#x3c; 0.01) but similar between TA and HC. The best diagnostic performance regarding CA was found for ECP and B-Eos with receiver operating characteristics area under curve (AUC) of 0.801 and 0.810, respectively. The optimal cutoff for ECP (29 μg/L) yielded a sensitivity and specificity of 70.3% and 81.4%. The corresponding AUCs for FeNO and FEV1/FVC were 0.732 and 0.670, respectively. ECP and B-Eos showed the highest AUCs (0.669 and 0.673) for differentiation between CA and TA. Combining ECP with FeNO and FEV1/FVC increased the odds ratio (OR) for having CA from OR 3.97–10.3 for the single biomarkers to OR 20.2 (95% confidence interval: 5.76–68.6). <b><i>Conclusion:</i></b> Our results show that serum ECP is a reliable biomarker in the diagnosis of childhood asthma, with additional value in combination with FeNO and FEV1/FVC, and that ECP can be an alternative to B-Eos.